Pharmaceuticals

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

A top university and a global clinical research firm unite to slash drug development timelines, aiming to bring innovative therapies to patients faster.

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

RenovoRx sets a key update call, juggling early RenovoCath device sales with its pivotal Phase III pancreatic cancer trial, a beacon for patients.

Biotech firm Ribo Life Science reveals a new platform targeting the kidney, heart, and fat tissue, signaling a major shift for RNA-based medicines.

An influential guidelines update expands options for a tough-to-treat bladder cancer, giving patients access to a novel gene therapy beyond its FDA label.

Curia announces major upgrades to its UK sterile manufacturing and US biologics platforms, a strategic move to accelerate drug development timelines.

The National Bleeding Disorders Foundation taps celebrity power for a live event, aiming to spotlight underdiagnosed conditions and transform advocacy.

A new oral drug is being tested with existing therapies, offering a two-pronged attack on the glycogen buildup that defines this debilitating rare disease.

With the FDA mandating a move from animal testing, BioIVT is positioning itself at the center of the NAMs revolution with key industry events and research.

ImmunoBrain's novel immunotherapy for Alzheimer's avoids key safety issues of other drugs and shows positive biomarker data in a Phase 1b trial.

LGM Pharma is investing $15 million to expand its Texas and Colorado sites, boosting domestic production of specialized drugs and fortifying the U.S. supply chain.

With a new CFO who helped steer a multi-billion dollar acquisition, Bambusa Therapeutics signals major growth plans for its innovative antibody platform.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

Ractigen's RAG-01 advances with NMPA approval, using RNA activation to fight bladder cancer by targeting a previously 'undruggable' gene.

A new drug shows unprecedented activity against all common cold viruses, a major breakthrough for millions suffering from chronic lung diseases.

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

A new $7 million deal will use a digital marketplace to deliver 16 million doses of a life-saving antibiotic to children in Burkina Faso. But can it work?